NYSE:CRL - New York Stock Exchange, Inc. - US1598641074 - Common Stock - Currency: USD
157.12
-0.37 (-0.23%)
The current stock price of CRL is 157.12 USD. In the past month the price increased by 9.71%. In the past year, price decreased by -21.31%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
TMO | THERMO FISHER SCIENTIFIC INC | 19.6 | 162.07B | ||
DHR | DANAHER CORP | 27.28 | 145.42B | ||
A | AGILENT TECHNOLOGIES INC | 22.48 | 34.61B | ||
IQV | IQVIA HOLDINGS INC | 14.53 | 28.41B | ||
MTD | METTLER-TOLEDO INTERNATIONAL | 29.88 | 25.12B | ||
WAT | WATERS CORP | 29.41 | 20.84B | ||
WST | WEST PHARMACEUTICAL SERVICES | 33.47 | 15.97B | ||
ILMN | ILLUMINA INC | 30.27 | 15.96B | ||
RVTY | REVVITY INC | 20.55 | 11.94B | ||
ICLR | ICON PLC | 10.94 | 11.93B | ||
TEM | TEMPUS AI INC | N/A | 10.56B | ||
QGEN | QIAGEN N.V. | 21.02 | 10.47B |
Charles River Laboratories International, Inc. engages in providing products and services to help pharmaceutical and biotechnology companies. The company is headquartered in Wilmington, Massachusetts and currently employs 18,600 full-time employees. The company went IPO on 2000-06-23. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. Its Research Models and Services segment includes three businesses that provide foundational tools that enable its clients to discover new molecules: Research Models, Research Model Services, and Cell Solutions. Its Discovery and Safety Assessment segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. Its Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions.
CHARLES RIVER LABORATORIES
251 Ballardvale St
Wilmington MASSACHUSETTS 01887 US
CEO: James C. Foster
Employees: 18600
Phone: 17812226000
The current stock price of CRL is 157.12 USD. The price decreased by -0.23% in the last trading session.
The exchange symbol of CHARLES RIVER LABORATORIES is CRL and it is listed on the New York Stock Exchange, Inc. exchange.
CRL stock is listed on the New York Stock Exchange, Inc. exchange.
24 analysts have analysed CRL and the average price target is 156.96 USD. This implies a price decrease of -0.1% is expected in the next year compared to the current price of 157.12. Check the CHARLES RIVER LABORATORIES stock analysts ratings, price target forecast and up-and down grades for more detailed information.
CHARLES RIVER LABORATORIES (CRL) has a market capitalization of 7.72B USD. This makes CRL a Mid Cap stock.
CHARLES RIVER LABORATORIES (CRL) currently has 18600 employees.
CHARLES RIVER LABORATORIES (CRL) has a support level at 135.62 and a resistance level at 150.02. Check the full technical report for a detailed analysis of CRL support and resistance levels.
The Revenue of CHARLES RIVER LABORATORIES (CRL) is expected to decline by -3.32% in the next year. Check the estimates tab for more information on the CRL EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
CRL does not pay a dividend.
CHARLES RIVER LABORATORIES (CRL) will report earnings on 2025-08-05, before the market open.
The PE ratio for CHARLES RIVER LABORATORIES (CRL) is 15.12. This is based on the reported non-GAAP earnings per share of 10.39 and the current share price of 157.12 USD. Check the full fundamental report for a full analysis of the valuation metrics for CRL.
The outstanding short interest for CHARLES RIVER LABORATORIES (CRL) is 5.36% of its float. Check the ownership tab for more information on the CRL short interest.
ChartMill assigns a technical rating of 4 / 10 to CRL. When comparing the yearly performance of all stocks, CRL is a bad performer in the overall market: 79.33% of all stocks are doing better.
ChartMill assigns a fundamental rating of 4 / 10 to CRL. CRL has only an average score on both its financial health and profitability.
Over the last trailing twelve months CRL reported a non-GAAP Earnings per Share(EPS) of 10.39. The EPS increased by 2.47% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -0.42% | ||
ROE | -0.99% | ||
Debt/Equity | 0.79 |
ChartMill assigns a Buy % Consensus number of 67% to CRL. The Buy consensus is the average rating of analysts ratings from 24 analysts.
For the next year, analysts expect an EPS growth of -6.08% and a revenue growth -3.32% for CRL